Ingenza launches UNVAIL to find novel proteins via AI-driven search

Edinburgh CRDMO Ingenza deploys AI-ML protein discovery to serve pharma, chemicals and sustainable fuels simultaneously.

By Disrupts Editorial Team Thu, 17 September 2026 AI level 2 of 5

AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean

A brightly lit modern laboratory features an automated liquid handler pipetting into microplates, surrounded by various scientific instruments, glassware, and white lab benches, with green trees visible outside large windows.

Ingenza, an Edinburgh-based engineering biology contract research, development and manufacturing organisation (CRDMO), has launched UNVAIL, an AI and machine-learning platform designed to identify previously uncharacterised proteins with superior industrial performance. The launch extends the company's inGenius biomanufacturing platform and positions Ingenza in a fast-moving race to replace chemistry-heavy industrial processes with biology-derived alternatives across pharmaceuticals, food, personal care and sustainable fuel production.

UNVAIL works by scanning public protein sequence datasets for distantly-related analogues to a target protein, then applying predictive models to score candidates for solubility, structural stability and the likelihood of beneficial mutations. The company says proteins identified through the system consistently outperform current industrial benchmarks on activity, stability and solubility, and are structurally distinct enough to be patentable, side-stepping intellectual property constraints that arise when sequences are too closely related to existing commercial proteins.

From discovery to the bioreactor

The platform sits at the front end of Ingenza's broader inGenius stack, which also includes the codABLE codon-optimisation tool (a separate AI-ML module that fine-tunes the DNA-level instructions used to express a protein in a chosen host organism) and a suite of twelve proprietary microbial and cell-based host systems for fermentation. The end-to-end architecture means a novel protein candidate can, in principle, move from computational discovery through strain engineering to upstream and downstream manufacturing without leaving Ingenza's infrastructure. Ian Fotheringham, President and Founder, framed UNVAIL as additive to an existing service model: "Now, we not only offer our customers accelerated strain, cell line and process development for their assets, but we can also provide them with novel, enhanced proteins, further optimising performance and cost-competitiveness."

The breadth of target industries listed in the launch is notable. Biocatalysis, using enzymes or whole-cell systems to drive chemical reactions, is already mature in detergent and food manufacturing. Its extension into sustainable fuels and fine chemicals is where the commercial frontier lies, and where AI-led protein discovery creates the sharpest wedge against incumbent petrochemical processes.

Convergence read-across: biology meets compute budgets

The strategic significance of UNVAIL extends well beyond Ingenza's client list. Protein discovery is becoming a compute-intensive discipline in the same way that drug-discovery genomics did in the 2010s, and that shift carries implications for several adjacent capital decisions.

First, the biomanufacturing sector is increasingly dependent on high-throughput AI inference, meaning that the energy and data-centre capacity strategies of contract manufacturers are quietly converging with those of cloud infrastructure providers. CRDMOs that own their computational stack, as Ingenza claims to do with inGenius, reduce their exposure to third-party model pricing and data-sovereignty risk, a consideration increasingly relevant to European life-sciences clients operating under GDPR and forthcoming EU AI Act obligations.

Second, the cross-sector reach of industrial proteins creates natural bridges for cross-vertical capital. Sovereign wealth and corporate balance sheets that are simultaneously funding green-chemistry transitions and pharmaceutical pipeline acceleration are natural buyers of the kind of platform that Ingenza is building, because a single protein-discovery engine can feed multiple portfolio companies across sectors. The broader competitive landscape includes well-capitalised players such as Ginkgo Bioworks and Zymergen's successor activities, as well as AI-native protein-design labs like Cradle Bio, all of which are attracting venture and strategic capital on the premise that biology is becoming programmable infrastructure.

For cross-sector allocators, the more consequential signal in the UNVAIL launch is less the specific capabilities announced and more the trajectory it represents: computational biology is moving from pharmaceutical adjacency into industrial materials, energy and food systems simultaneously, compressing the timescale in which investors must form a view across all four.